RESUMO
Objective: To study the effects of glycosaminoglycan from scallop skirt (SS-GAG) on the expression of vascular endothelial growth factor (VEGF) and the mechanism of anti-atherosclerosis action of SS-GAG. Methods: U937 cells were incubated with 80mg/L oxidized low density lipoprotein (ox-LDL) for 48h to establish a macrophage-derived foam cell model. In addition, U937 cells were divided into 6 groups: ①control group; ②ox-LDL group; ③ox-LDL+200mg/L SS-GAG group; ④ox-LDL+400 mg/L SS-GAG group; ⑤ox-LDL+800 mg/L SS-GAG group; ⑥ox-LDL +Heparin 100 mg/L group.After 48h's incubation, the concentration of VEGF in the medium was determined by ELISA. Results: The expression of VEGF in U937 foam cells was obviously higher than that of the control group. After treatment with heparin (100 mg/L) and SS-GAG of different concentrations (200mg/L, 400 mg/L, 800 mg/L), the expression of VEGF decreased obviously, especially in the ox-LDL+800 mg/L SS-GAG group (P＜0.01). Conclusion: The antiatherogenic effect of SS-GAG is probably due to its ability to inhibit VEGF expression.
RESUMO
Objective: To study the effects of glycosaminoglycan from scallop skirt (SS-GAG) on the expression of vascular endothelial growth factor (VEGF) and the mechanism of anti-atherosclerosis action of SS-GAG. Methods: U937 cells were incubated with 80mg/L oxidized low density lipoprotein (ox-LDL) for 48h to establish a macrophage-derived foam cell model. In addition, U937 cells were divided into 6 groups: ①control group; ②ox-LDL group; ③ox-LDL+200mg/L SS-GAG group; ④ox-LDL+400 mg/L SS-GAG group; ⑤ox-LDL+800 mg/L SS-GAG group; ⑥ox-LDL +Heparin 100 mg/L group.After 48h's incubation, the concentration of VEGF in the medium was determined by ELISA. Results: The expression of VEGF in U937 foam cells was obviously higher than that of the control group. After treatment with heparin (100 mg/L) and SS-GAG of different concentrations (200mg/L, 400 mg/L, 800 mg/L), the expression of VEGF decreased obviously, especially in the ox-LDL+800 mg/L SS-GAG group (P＜0.01). Conclusion: The antiatherogenic effect of SS-GAG is probably due to its ability to inhibit VEGF expression.